Spinal cord astrocytes are specialized glial cells that play critical roles in maintaining spinal cord homeostasis, supporting motor neurons, and regulating the neural microenvironment. In neurodegenerative diseases, particularly amyotrophic lateral sclerosis (ALS), spinal cord astrocytes undergo dramatic phenotypic changes that contribute to disease progression through loss of supportive functions and gain of toxic properties.
This page examines the morphology, normal functions, and pathological transformations of spinal cord astrocytes across multiple neurodegenerative conditions, with emphasis on therapeutic implications.
¶ Morphology and Classification
The spinal cord contains several morphologically and functionally distinct astrocyte populations:
| Subtype |
Location |
Morphology |
Primary Functions |
| Protoplasmic astrocytes |
Gray matter |
Complex branching processes |
Metabolic support, synapse maintenance |
| Fibrous astrocytes |
White matter |
Long radial processes |
Myelin maintenance, axon guidance |
| Velate astrocytes |
Surrounding neurons |
Sheet-like processes |
Neuronal ensheathment |
| Pituicytes |
Neurohypophysis |
Oval cell bodies |
Neurovascular coupling |
Spinal cord astrocytes are characterized by:
- Somatic morphology: Small cell bodies (10-20 μm diameter) with irregular nuclei
- Process architecture: Extensively branched processes forming perineuronal nets
- Domain organization: Tile-like territorial domains with minimal overlap
- Endfoot coverage: Perivascular endfeet ensheathing blood vessels
Spinal cord astrocytes provide essential metabolic support to motor neurons:
- Lactate shuttle: Astrocytic glycolysis produces lactate transported to neurons as energy substrate [@pellerin2007]
- Glycogen storage: Stores glycogen for rapid energy supply during neural activity
- Ion buffering: Regulates extracellular K+ accumulation during neuronal firing
- pH regulation: Maintains acid-base homeostasis through bicarbonate transport
Astrocytes regulate synaptic transmission through:
- Glutamate uptake: EAAT1/GLAST and EAAT2/GLT-1 transporters clear synaptic glutamate
- GABA recycling: uptake and metabolism of GABA through GAT-3
- Glutamine synthesis: Convert glutamate to glutamine for neuronal recycling
¶ Blood-Spinal Cord Barrier Maintenance
- Perivascular endfeet: Cover ~90% of spinal cord capillaries
- Tight junction support: Maintain barrier integrity through astrocyte-derived signals
- Angiogenesis regulation: Coordinate new vessel formation during development
Spinal cord astrocytes in ALS undergo profound transformations that contribute to motor neuron death:
- GFAP upregulation: 5-10 fold increase in glial fibrillary acidic protein expression
- Hypertrophy: Enlarged cell bodies with increased process branching
- Proliferation: Enhanced astrocyte division in response to motor neuron injury
- Diminished glutamate uptake: 40-60% reduction in GLT-1 expression leads to excitotoxicity
- Impaired metabolic coupling: Disrupted lactate shuttle compromises neuronal energy
- Potassium buffering deficit: Reduced Kir4.1 function leads to extracellular K+ accumulation
Astrocytes in ALS secrete factors toxic to motor neurons:
| Toxic Factor |
Mechanism |
Evidence |
| SOD1 aggregates |
Cell-to-cell propagation of mutant protein |
[@tokuda2023] |
| Pro-inflammatory cytokines (IL-1β, TNF-α) |
NF-κB activation in astrocytes |
|
| Reactive oxygen species |
NADPH oxidase activation |
[@cabezas2012] |
| Excitotoxic glutamate |
Impaired reuptake, increased release |
[@foran2012] |
Spinal cord involvement in PD extends beyond the brain:
- α-Synuclein aggregation: Astrocytes accumulate Lewy body-like inclusions
- Neuroinflammation: Pro-inflammatory cytokine production in spinal cord glia
- Motor neuron contributions: Ventral horn astrocyte dysfunction may affect spinal motor circuits
- Spinal cord involvement: Early tau pathology in spinal cord neurons
- Astrocytic responses: GFAP upregulation in spinal cord regions
- Pain pathway dysfunction: Astrocyte contributions to small fiber neuropathy
- GLT-1 restoration: AAV-mediated GLT-1 gene delivery to restore glutamate uptake
- Kir4.1 modulation: Targeting potassium channels to improve neuronal environment
- BDNF delivery: Astrocyte-specific expression of neurotrophic factors
- Anti-inflammatory agents: Minocycline, ibuprofen reduce astrocyte reactivity
- Metabolic enhancers: Lactate supplementation, pyruvate supplementation
- GFAP inhibitors: Targeting intermediate filament accumulation
| Approach |
Target |
Development Stage |
Reference |
| AAV-GLT-1 |
Glutamate uptake restoration |
Preclinical |
[@p供奉2019] |
| Anti-SOD1 antibodies |
Cell-to-cell transmission |
Phase 1/2 |
NCT05633416 |
| Ilostat |
IL-1β modulation |
Phase 1 |
NCT05238602 |